Mutation Found in Amish Said to Make Some Live 10 Years Longer

Henrietta Brewer
November 16, 2017

According to world experts in the field of genetic engineering, gene telomeres SEPRINE1 representatives of the Amish community longer than the average person.

An Amish toddler's head wound in the early 1990s, which bled uncontrollably and almost killed her, has led decades later to a promising new anti-aging therapy now being tested in Japan, according to researchers at Northwestern University Feinberg School of Medicine. The secluded group allowed some 40 doctors and other medical staff to take samples and run tests including echocardiograms, blood pressure readings, pulse wave velocity, pulmonary function evaluations, and urine samples.

A toddler who had bumped her head at the age of three had almost died of uncontrollable bleeding in the early 1990s.

The mutation that Vaughan's team zeroed in on affects plasminogen activator inhibitor-1 (PAI-1), a protein known for its role in promoting blood clotting.


Trials are already underway into drugs that can slightly reduce blood levels of PAI-1. The investigators found varying degrees of the gene among the 10,000 people who came to make up their investigational family tree.

Those who have it live to be 85, on average, significantly longer than the predicted average life span of 71 for Amish people in general.

However, Vaughan's team found that those with a mutation on only one of these copies didn't have the bleeding disorder.

"This is the only kindred on the planet that has this mutation", Vaughan said.


The new findings of the 177 Amish indicates that they have lower levels of PAI-1.

Those with a single copy of the mutation also had a lower incidence of diabetes, lower insulin levels after fasting, slightly lower blood pressure, and possibly more flexible blood vessels. It is noted, the unit of heredity destroys risky for the cardiovascular system clots accumulating in the blood vessels. They hope to test it in the USA within the next six months, following FDA approval. This drug is now in Phase 2 clinical trials to test its efficacy in humans.

Northwestern University researchers have partnered with Japan's Tohoku University to develop and test an experimental drug that would inhibit the action of PAI-1, like in Amish people with the mutant gene.

So, Vaughan plans to seek permission from the U.S. Food and Drug Administration to start a trial in the United States as early as next year to examine the effects of using the drug to lower PAI-1 in people who are obese or insulin-resistant. A paper describing this discovery was recently published in Science Advances.


Other reports by iNewsToday

FOLLOW OUR NEWSPAPER